000094550 001__ 94550 000094550 005__ 20210902121751.0 000094550 0247_ $$2doi$$a10.1177/2042018820931291 000094550 0248_ $$2sideral$$a118594 000094550 037__ $$aART-2020-118594 000094550 041__ $$aeng 000094550 100__ $$0(orcid)0000-0002-2801-416X$$aPérez-López, Faustino R. 000094550 245__ $$aVitamin D supplementation after the menopause 000094550 260__ $$c2020 000094550 5060_ $$aAccess copy available to the general public$$fUnrestricted 000094550 5203_ $$aThe purpose of this review was to assess recent evidence regarding the effects of low vitamin D levels on some highly prevalent clinical conditions of postmenopausal women. We reviewed and selected recent literature regarding menopause-related conditions associated with vitamin D deficiency and interventions to manage them. Low circulating 25-hydroxyvitamin D (25(OH)D) levels related to menopause are linked to diet, lifestyle, changes in body composition, insulin sensitivity, and reduced physical activity. Vitamin D supplementation increases serum 25(OH)D levels while normalizing parathyroid hormone and bone markers, and in women with serum 25(OH)D levels below 10 ng/ml supplementation may improve bone mineral density. Low vitamin D status has been associated with the metabolic syndrome, high triglyceride levels, and low high-density lipoprotein cholesterol levels. When compared with placebo, vitamin D supplementation may lower the risk of the metabolic syndrome, hypertriglyceridemia, and hyperglycemia. There is an inverse relationship between fat mass and serum 25(OH)D levels and, therefore, the dosage of supplementation should be adjusted according to the body mass index. Although vitamin D supplementation may improve glucose metabolism in prediabetic subjects, data regarding muscle strength are conflictive. There is evidence that vitamin D over-treatment, to reach extremely high circulating 25(OH)D levels, does not result in better clinical outcomes. The identification and treatment of vitamin D deficiency in postmenopausal women may improve their general health and health outcomes. Vitamin D supplementation should preferably be based on the use of either cholecalciferol or calcifediol. 000094550 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/ 000094550 590__ $$a3.565$$b2020 000094550 591__ $$aENDOCRINOLOGY & METABOLISM$$b87 / 145 = 0.6$$c2020$$dQ3$$eT2 000094550 592__ $$a0.889$$b2020 000094550 593__ $$aEndocrinology, Diabetes and Metabolism$$c2020$$dQ2 000094550 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000094550 700__ $$aChedraui, Peter 000094550 700__ $$aPilz, Stefan 000094550 773__ $$g11 (2020), 1-13$$pTher. adv. endocrinol. metab.$$tTherapeutic Advances in Endocrinology and Metabolism$$x2042-0188 000094550 8564_ $$s118780$$uhttps://zaguan.unizar.es/record/94550/files/texto_completo.pdf$$yVersión publicada 000094550 8564_ $$s32262$$uhttps://zaguan.unizar.es/record/94550/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000094550 909CO $$ooai:zaguan.unizar.es:94550$$particulos$$pdriver 000094550 951__ $$a2021-09-02-09:49:09 000094550 980__ $$aARTICLE